stocktitan.netAUG 211 min read$RGEN

Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan

Repligen (RGEN) CEO Olivier Loeillot exercised 5,426 stock options at $141.79 per share and sold the shares at $180 each under a 10b5-1 plan, according to a Form 4 filing. The transaction occurred on August 20, 2026, and 10,852 options remain outstanding. Additional shares will vest in 2026 and 2027.

Original reporting

stocktitan.net

Published Aug 21, 2026, 8:07 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 6:23 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$RGEN

Neutral

medium confidence

Mentioned

$RGEN

Relevance

6/10

alphai data visualization · based on stocktitan.net

Decision brief

The 30-second read

$RGENNeutralLow

Why it matters

The disclosed insider sale provides fresh data on insider sentiment and potential short‑term supply pressure.

Market read

New insider transaction for a micro‑cap biotech, modest relevance for traders monitoring insider activity.

What to watch

Vesting schedule continues; future option exercises may offset current dilution.

Relevance 6/10Novelty 8/10Timing: post‑market Aug 20, 2026

Background

Repligen (RGEN) filed a Form 4 reporting the CEO's option exercise and share sale under a 10b5‑1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RGENNeutralMedium confidence

Context

Form 4 disclosed CEO Olivier Loeillot exercised options and sold 5,426 shares at $180, a new insider transaction.

Expected impact

Potential modest downward pressure on RGEN price in the near term.

Evidence & confidence

The sale size is notable for a micro‑cap but not large enough to trigger a sharp move; market may view it as routine.

Market effects

Sector

Minimal impact on the biotech sector; insider trades are company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a negative signal.

Key entities

Executive
Olivier Loeillot
CEO of Repligen who exercised options and sold shares.
Company
Repligen Corp
Biotech firm listed on NASDAQ (RGEN).

Read at source ← All news

AUG 27

$RGENHighAI 8/10

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).

finance.yahoo.com2 min

AUG 25

$MRKHighAI 8/10

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

yahoo.com3 min

AUG 20

$RGENHighAI 8/10

Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal

Repligen (RGEN) shares rose 3.5% following strong Q2 2026 results, raised 2026 guidance, and the planned BioLife Solutions acquisition. Revenue was $204M with double-digit YoY growth. Full-year 2026 organic revenue growth guidance increased to 10.5%-13.5%, and adjusted EPS outlook raised to $2.03-$2.09. The BioLife deal, valued at $1.5B, is expected to expand Repligen's cell therapy tools.

quiverquant.com2 min

AUG 19

$TEMHighAI 8/10

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

finance.yahoo.com2 min

AUG 6

$BLFSMed

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

BioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.

stocktitan.net2 min

JUL 30

$RGENHighAI 9/10

Repligen Q2 Earnings Call Highlights

Repligen (NASDAQ:RGEN) reported Q2 growth in chromatography revenue in the low double digits, driven by OPUS columns and demand from CDMOs and biopharma. Filtration revenue rose slightly, with headwinds tied to gene therapy issues, ATF customer inventory, site readiness delays, and the Polymem divestiture. Repligen raised 2026 revenue outlook to $813M-$834M and EPS to $2.03-$2.09, excluding BioLife acquisition.

yahoo.com7 min